292 related articles for article (PubMed ID: 15358286)
1. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
2. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
3. Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
Kettler K; Sakowski J; Silber K; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2003 Apr; 11(7):1521-30. PubMed ID: 12705292
[TBL] [Abstract][Full Text] [Related]
4. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
Kettler K; Wiesner J; Silber K; Haebel P; Ortmann R; Sattler I; Dahse HM; Jomaa H; Klebe G; Schlitzer M
Eur J Med Chem; 2005 Jan; 40(1):93-101. PubMed ID: 15642414
[TBL] [Abstract][Full Text] [Related]
5. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
[TBL] [Abstract][Full Text] [Related]
6. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
Mitsch A; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
[TBL] [Abstract][Full Text] [Related]
7. Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides.
Sakowski J; Sattler I; Schlitzer M
Bioorg Med Chem; 2002 Feb; 10(2):233-9. PubMed ID: 11741771
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
[TBL] [Abstract][Full Text] [Related]
9. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Böhm M; Sattler I
Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
[TBL] [Abstract][Full Text] [Related]
10. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by arylthienylacryloylaminobenzophenones.
Mitsch A; Altenkämper M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2005 Jan; 338(1):9-17. PubMed ID: 15674808
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
Wiesner J; Mitsch A; Jomaa H; Schlitzer M
Bioorg Med Chem Lett; 2003 Jul; 13(13):2159-61. PubMed ID: 12798326
[TBL] [Abstract][Full Text] [Related]
12. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective farnesyl transferase inhibitors.
Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
[TBL] [Abstract][Full Text] [Related]
14. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
[No Abstract] [Full Text] [Related]
15. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
[No Abstract] [Full Text] [Related]
16. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity.
Wiesner J; Ortmann R; Mitsch A; Wissner P; Sattler I; Jomaa H; Schlitzer M
Pharmazie; 2003 Apr; 58(4):289-90. PubMed ID: 12749417
[No Abstract] [Full Text] [Related]
17. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Sattler I
Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
[TBL] [Abstract][Full Text] [Related]
18. Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements.
Sakowski J; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2002 Apr; 335(4):135-42. PubMed ID: 12112033
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.
Lin NH; Wang L; Wang X; Wang GT; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2004 Oct; 14(20):5057-62. PubMed ID: 15380198
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2001; 19():149-64. PubMed ID: 11686012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
